Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

Core Insights - The APEX Phase 2 trial results for zumilokibart (APG777) indicate durable maintenance of response in patients with moderate-to-severe atopic dermatitis (AD) over 52 weeks, with significant efficacy observed in both 3- and 6-month dosing regimens [2][3][4] - Zumilokibart demonstrated a potentially best-in-class profile, achieving over 99% inhibition of IL-13, leading to rapid and sustained relief of itch and lesions [3][8] - The company plans to initiate Phase 3 trials in the second half of 2026, with a potential commercial launch of zumilokibart anticipated in 2029 [3][4][9] Clinical Trial Results - In the 52-week maintenance portion of the APEX trial, 75% and 85% of patients maintained Eczema Area and Severity Index (EASI-75) scores with 3- and 6-month dosing, respectively [5][9] - The validated Investigator's Global Assessment (vIGA) 0/1 maintenance of response was 86% for 3-month dosing and 78% for 6-month dosing among Week 16 responders [9] - Deepening of response was observed across all lesional and itch endpoints for both dosing regimens, indicating a highly differentiated treatment profile [6][9] Future Developments - APEX Part B, a placebo-controlled dose optimization trial, is set to read out 16-week data in the second quarter of 2026, which will support the initiation of Phase 3 trials [4][6] - The upcoming Phase 3 trials are expected to further evaluate the efficacy and safety of zumilokibart, with results from Part B anticipated to influence clinical and regulatory outcomes [4][6][9] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology markets, including AD, asthma, and eosinophilic esophagitis (EoE) [2][9] - The company aims to address the challenges of existing therapies by providing treatments with less frequent dosing and improved patient compliance [8][10] - Zumilokibart is positioned as a potential game-changer in the treatment of AD, with plans for expansion into other indications based on its promising profile [8][10]